{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:05:00Z","timestamp":1793361900417,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40265-020-01414-9","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T20:02:37Z","timestamp":1602014557000},"page":"1739-1744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Oliceridine: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"1414_CR1","unstructured":"Trevena Inc. Trevena announces FDA has set PDUFA date of August 7, 2020 for oliceridine [media release]. 5 Mar 2020. https:\/\/www.trevena.com\/."},{"issue":"3","key":"1414_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.112.201616","volume":"344","author":"SM DeWire","year":"2013","unstructured":"DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708\u201317.","journal-title":"J Pharmacol Exp Ther"},{"key":"1414_CR3","unstructured":"Trevena Inc. OLINVYKTM (oliceridine) injection, for intravenous use, [controlled substance schedule pending]: US prescribing information. 2020. https:\/\/olinvyk.com\/. Accessed 12 Aug 2020."},{"key":"1414_CR4","unstructured":"US Food & Drug Administration. FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings [media release]. 7 Aug 2020. https:\/\/www.fda.gov\/."},{"key":"1414_CR5","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.2147\/JPR.S217563","volume":"12","author":"SD Bergese","year":"2019","unstructured":"Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein selective agonist at the \u00b5-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J Pain Res. 2019;12:3113\u2013266.","journal-title":"J Pain Res"},{"key":"1414_CR6","unstructured":"Trevena Inc, Pharmbio Korea. Trevena and Pharmbio Korea announce license and commercialization agreement for oliceridine in South Korea [media release]. 27 Apr 2018. https:\/\/www.trevena.com\/."},{"key":"1414_CR7","unstructured":"Trevena Inc. Trevena Inc. and Jiangsu Nhwa Pharmaceutical Co. Ltd announce license agreement for oliceridine in China [media release]. 1 May 2018. https:\/\/www.trevena.com\/"},{"issue":"6 Suppl 1","key":"1414_CR8","doi-asserted-by":"publisher","first-page":"S-758","DOI":"10.1016\/S0016-5085(18)32629-5","volume":"154","author":"JC Jacob","year":"2018","unstructured":"Jacob JC, David B, Khan A, et al. The effect of a G-protein biased ligand, TRV130, on opioid-induced constipation [abstract no. Mo1578]. Gastroenterology. 2018;154(6 Suppl 1):S-758.","journal-title":"Gastroenterology"},{"issue":"3","key":"1414_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jcph.207","volume":"54","author":"DG Soergel","year":"2014","unstructured":"Soergel DG, Subach RA, Sadler B, et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014;54(3):351\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1414_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/cpdd.750","volume":"9","author":"AN Nafziger","year":"2020","unstructured":"Nafziger AN, Arscott KA, Cochrane K, et al. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine. Clin Pharmacol Drug Dev. 2020;9(5):639\u201350.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1414_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/JPR.S171013","volume":"12","author":"ER Viscusi","year":"2019","unstructured":"Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927\u201343.","journal-title":"J Pain Res"},{"issue":"7","key":"1414_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/papr.12801","volume":"19","author":"NK Singla","year":"2019","unstructured":"Singla NK, Skobieranda F, Soergel DG, et al. APOLLO-2: A randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019;19(7):715\u201331.","journal-title":"Pain Pract"},{"key":"1414_CR13","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.2147\/JPR.S137952","volume":"10","author":"N Singla","year":"2017","unstructured":"Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel \u00b5-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017;10:2413\u201324.","journal-title":"J Pain Res"},{"key":"1414_CR14","unstructured":"Trevena Inc. FDA Advisory Committee Briefing Document. Oliceridine: meeting of the Anesthetic and Analgesic Drug Products Advisory Committee. 2018. 16 Sep 2020. https:\/\/www.fda.gov\/media\/121230\/download."}],"updated-by":[{"DOI":"10.1007\/s40265-020-01425-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01414-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01414-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01414-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T02:09:58Z","timestamp":1633486198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01414-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":14,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01414-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"6 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article can be found online.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. Markham is a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}